5PSQ-058 Comparative effectiveness of regorafenib versus trifluridine/tipiracil in metastatic colorectal cancer

BACKGROUND: Regorafenib and trifluridine/tipiracil (TAS-102) are indicated in metastatic colorectal cancer (mCRC) refractary to standard therapies. Both have been approved after being compared to placebo, so comparative studies with other therapies are needed. PURPOSE: To compare effectiveness and s...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Eur J Hosp Pharm
Autores principales: Arrieta, M, Lázaro, A, García, C, Rodríguez, P, Ortiz, S, Ferrari, JM
Formato: Artigo
Lenguaje:Inglês
Publicado: BMJ Group 2018
Materias:
Section 5: Patient safety and quality assurance
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535839/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.412
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares